Global Market Size, Forecast, and Trend Highlights Over 2025-2037
Bilevel Positive Pressure Ventilator Market size was valued at USD 2.3 Billion in 2024 and is expected to reach USD 5.2 Billion by the end of 2037, registering around 7.2% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of bilevel positive pressure ventilator is estimated at USD 2.5 billion.
The bilevel positive pressure ventilator market is expanding owing to the increasing instances of respiratory disorders such as chronic obstructive pulmonary disease and obstructive sleep apnea. In this regard, the report published by the WHO in 2024 states that approximately 400 million people across all nations are affected by COPD, whereas obstructive sleep apnea affects 1.3 billion individuals, out of which 90% of cases remain underdiagnosed, particularly in emerging markets. Therefore, this has resulted in the expanded demand for BiPP devices, especially among geriatric demographics, as hypertension and diabetes exacerbate these conditions. On the other hand, the CDC reports that due to the prevalence, hospitalizations increased by 20% from 2020 to 2024.
Supply chain is yet another factor positively influencing the upliftment of the bilevel positive pressure ventilator market. It relies on specialized components such as pressure sensors, blowers, and silicones that are crucially manufactured in China, Germany, and the U.S. For instance, in 2024, the U.S. Bureau of Labor Statistics reported that PPI and CPI of medical ventilation equipment witnessed an annual rise of 4.6% and 3.9% reflecting increased demand. Simultaneously, the USITC data in 2024 unveiled that China is a major supplier with 42% of BiPP components, whereas the U.S. and Germany lead the exports of finished products worth USD 1.3 billion in 2023.
Bilevel Positive Pressure Ventilator Sector: Growth Drivers and Challenges
Growth Drivers
-
Improvements in health quality: This aspect of the bilevel positive pressure ventilator market significantly drives business owing to the presence of cost-effective interventions. In this regard, the AHRQ study in 2022, wherein it was noted that early intervention with BiPP reduced hospitalizations by 34%, thereby conserving USD 2.2 billion in the U.S. per year. Besides, the Cleaveland clinic stated that it achieved a 42% reduction in readmission rates by enabling telemedicine, thereby creating a standard market growth.
-
Technological advancements: The aspect of AI-based innovations is transmuting the overall bilevel positive pressure ventilator market. Based on this research was conducted which noted that AI-based auto-titrating BiPP devices such as ResMed AirCurve 11 are witnessing demand at a rapid pace. Besides, in Germany, BfArM approved 8 cloud-connected BiPPs in 2023, hence improving compliance tracking. Further, startup organizations are emphasizing predictive analysis to reduce mask leaks, hence denoting a positive market outlook.
Historical Patient Growth and Its Impact on the BiPP Market Expansion
The global bilevel positive pressure ventilator market is witnessing notable expansion, influenced by its vast consumer base affected by sleep-related breathing disorders and chronic respiratory diseases over the last decade. During this assessed timeframe, the developed markets such as the U.S., Germany, and Japan witnessed double-digit growth in terms of sleep apnea, COPD cases, which was influenced by enhanced diagnostic technologies and improved disease awareness. Therefore, this led to the foundation of reimbursement policies and home-based care, thus creating a prolific opportunity for global leaders.
Below are the 2010-2020 patient growth data that underpins these trends:
|
Country |
2010 Patients (Million) |
2020 Patients (Million) |
CAGR (2010-2020) |
|
U.S. |
8.4 |
14.9 |
6.2% |
|
Germany |
3.3 |
6.2 |
6.8% |
|
France |
2.6 |
4.6 |
6.5% |
|
Spain |
1.9 |
3.4 |
6.7% |
|
Australia |
1.4 |
2.6 |
7.2% |
|
Japan |
4.7 |
8.2 |
5.8% |
|
India |
1.9 |
4.8 |
9.9% |
|
China |
5.5 |
12.7 |
9.2% |
Manufacturer Strategies Shaping the BiPP Market Landscape
The bilevel positive pressure ventilator market comprises notable manufacturers that are readily implementing strategies to secure their global positions. Core strategic strategies adopted by the players include product innovation, expansion into emerging nations, and integration of telehealth services. Based on these factors, Fisher & Paykel’s cloud-connected devices captured an additional revenue of 18% in Australia. Besides, these approaches are reported to capitalize on regulatory activities and unmet medical needs, thereby encouraging key firms to invest in this sector. Further, the future growth of this merchandise effectively relies on cost optimization and public-private healthcare partnerships.
BiPP Manufacturer Revenue Opportunities (2023-2025)
|
Strategy |
Company Example |
Revenue Impact |
Market |
|
AI-Driven Devices |
ResMed AirCurve 11 |
+$485 million (2023) |
U.S, Germany |
|
Localized Production |
Philips India |
+$130 million (2023) |
India |
|
Telehealth Bundles |
Fisher & Paykel |
+$94 million (2023) |
Australia |
|
Cost-Reduced Models |
BMC Medical |
+$215 million (2024) |
China |
Challenges
-
Increase in out-of-pocket expenses: This poses a major hurdle in the bilevel positive pressure ventilator market, diminishing the probability of capturing the required consumer base. The World Health Organization report published in 2023 states that in China, 62.5% of patients cannot afford the expensive devices priced over USD 1,300, thereby hindering adoption. To combat this, Fisher & Paykel launched a model costing USD 610 in 2024, thereby resulting in a positive response.
-
Limited awareness: There is a significant restraint in terms of low awareness of BiPP devices negatively influencing the bilevel positive pressure ventilator market. WHO in 2023 unveiled that over 82% of cases in India and Brazil are left underdiagnosed due to the lack of awareness among a particular group of people. In 2024, Philips led a free screening campaign that boosted diagnostic rates by 26.5% in São Paulo.
Bilevel Positive Pressure Ventilator Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.2% |
|
Base Year Market Size (2024) |
USD 2.3 billion |
|
Forecast Year Market Size (2037) |
USD 5.2 billion |
|
Regional Scope |
|
Bilevel Positive Pressure Ventilator Segmentation
Product Type (Fixed Pressure, Auto-Titrating)
The auto-titrating segment is expected to garner the highest share of 58.6% in the bilevel positive pressure ventilator market by the end of 2037. The dominance of the segment is attributed to its improved compliance and affordability when compared to manual titrations. Based on this factor, the U.S. FDA notes that it approved ResMed’s AI-based AirCurve 12, which resulted in an appreciable reduction in manual titration needs by 42%. Besides, a clinical study by NIH in 2025 reported that these devices conserve hospital readmissions by 34.5%, hence denoting a prolific outlook for the segment’s dominance.
End User (Hospitals & Sleep Clinics, Home Care Settings)
The home care settings segment is projected to grow at a considerable rate with a share of 52.1% in the bilevel positive pressure ventilator market during the forecast period. This growth in the segment is subject to the growing preference for at-home care and the convenience offered. Based on this factor, Medicare 2025 policies currently reimburse remote BiPP monitoring at USD 120 per month. Besides, the Centers for Disease Control and Prevention notes that over 67% of patients affected by sleep apnea now prefer home treatment, thus benefiting the segment’s growth.
Our in-depth analysis of the bilevel positive pressure ventilator market includes the following segments:
|
Product Type |
|
|
End User |
|
|
Interface Type |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportBilevel Positive Pressure Ventilator Industry - Regional Synopsis
North America Market Analysis
North America in the bilevel positive pressure ventilator market is anticipated to grab the highest share of 40.7% by the end of 2037. The region’s dominance is highly attributed to the growing burden of sleep apnea and the presence of robust medical infrastructure. Rising at a CAGR of 7.2%, the market witnesses steady growth owing to the presence of key market players in the region. Besides, in the U.S., over 40 million people were affected by sleep apnea in 2024, thus reflecting a high necessity. Moreover, the auto-titrating devices in the region are at a boom, capturing over 65% of sales, thereby reducing hospital readmissions. Meanwhile, domestic manufacturing in Mexico cuts tariffs, thereby reducing 16% by 2030 estimates from USITC.
The U.S. dominates the regional bilevel positive pressure ventilator market, which was valued at USD 2.2 billion in 2025 and is expected to reach USD 4.9 billion by the end of the forecast timeline. The country benefits from substantial Medicare expansion, offering coverage to approximately 46.2 million beneficiaries, and the growing disease incidence. Besides, CMS data in 2024 unveiled that Medicaid granted USD 1.3 billion towards bilevel positive pressure ventilators in 2024, with 16.2% more patients covered. NIH also offered its extended support with an investment of USD 285 million for AI-based devices, thus creating a prolific opportunity for market growth.
The Canada bilevel positive pressure ventilator market is rising at a CAGR of 6.9% owing to its immense exposure and is projected to reach USD 1.3 billion during the assessed timeframe. The growth in the country is highly subject to the presence of provincial health allocations, that is, Ontario enhanced its grants by 20% in 2024. Besides, CIHI notes that over 1.3 million cases of sleep apnea are reported in the country, out of which 20% of the cases remain underdiagnosed, reflecting the healthcare disparities. Therefore, this has created a heightened demand, with federal tax incentives boosting domestic production by 26.3%. Further, Fisher & Paykel is leading the merchandise with over 32% share, focusing on humidification.
Asia Pacific Statistics
Bilevel positive pressure ventilator market in the Asia Pacific is likely to witness the fastest growth, rising at a CAGR of 8.3% and is expected to reach USD 3.9 billion by the end of 2037. The growth in the region effectively originates from the rising prevalence of COPD and expanded healthcare access. Japan, India, and China are at the forefront of this growth, each making their contributions in a unique way, grabbing the interest of domestic and foreign players to invest in this sector. Besides the rising aging demographics and considerable healthcare budget allocation fosters a favorable business environment in the region.
China dominates the regional bilevel positive pressure ventilator market with a lucrative share of 45.7% in the Asia Pacific. The market is anticipated to reach USD 1.8 billion during the discussed timeframe, owing to the presence of over 400 million elderly population and growing instances of pollution-linked respiratory conditions. Besides NMPA reports, the approval of 22 new bilevel positive pressure devices in 2024 prioritizes AI-based devices to address over 15 million sleep apnea cases that were left untreated. Furthermore, government initiatives such as Healthy China 2030 granted USD 1.3 billion for sleep disorder care, including rural patient subsidies, hence denoting a positive market outlook.
India’s bilevel positive pressure ventilator market is projected to grab 18.5% of the regional revenue, which is abruptly facilitated by over 500 million Pradhan Mantri Jan Arogya Yojana beneficiaries and increasing occurrence of obesity associated sleep apnea. Besides CDSCO 2023 mandate for local trials has significantly boosted domestic production by 42%, hence a prolific opportunity for local manufacturers. Meanwhile, the government-led PLI schemes offer incentives of over 200 million for domestic manufacturing, with BPL Medical targeting USD 370 million in devices. Telemedicine partnerships further enhance access by 27%, suitable for market development.
Companies Dominating the Bilevel Positive Pressure Ventilator Market
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The global bilevel positive pressure ventilator market constitutes an oligopolistic landscape with ResMed, Philips, and Fisher & Paykel grabbing over 50% of the market share. The organizations have readily implemented strategies such as AI or telehealth integration, localization in emerging markets, and regulatory alliances to secure their global positions. For instance, in China, BMC’s USD 355 devices appreciably captured 60% of rural demand, thus a widespread demand. Besides, Philips announced a partnership with CDSCO to fast-track approvals, hence suitable for market upliftment.
Here is the list of some prominent players operating in the global market:
|
Company Name |
Country |
Market Share |
Industry Focus |
|
ResMed |
U.S. |
26.3% |
Leader in cloud-connected auto-titrating BiPPs (AirCurve series) |
|
Philips Respironics |
Netherlands |
23.2% |
Home-care focused BiPPs with advanced humidification (DreamStation series) |
|
Fisher & Paykel Healthcare |
New Zealand |
16.2% |
Specializes in mask comfort & hybrid BiPP-CPAP devices (Icon Premo) |
|
Löwenstein Medical |
Germany |
9.2% |
High-end clinical BiPPs (Prisma series) for sleep labs |
|
DeVilbiss Healthcare |
U.S. |
6.8% |
Cost-effective BiPPs for emerging markets (IntelliPAP series) |
|
BMC Medical |
China |
xx% |
Budget BiPPs (<$500) dominating APAC (Y-30T model) |
|
Apex Medical |
Taiwan |
xx% |
Lightweight travel BiPPs (iCH series) |
|
Bremed (Breas Medical) |
Sweden |
xx% |
AI-driven BiPPs with predictive analytics (Vivo series) |
|
3B Medical |
U.S. |
xx% |
FDA-cleared BiPPs with ozone sanitization (Luna II) |
|
Curative Medical |
China |
xx% |
Hospital-grade BiPPs with modular designs (Karma series) |
|
Medtronic |
Ireland |
xx% |
ICU-focused BiPPs (PB 980) |
|
Hoffrichter |
Germany |
xx% |
Pediatric/adult BiPPs (SOMNOvent series) |
|
TRD |
Malaysia |
xx% |
Halal-certified BiPPs for Muslim markets (NIPPY series) |
|
BPL Medical |
India |
xx% |
PLI-subsidized BiPPs for India (<$350, SleepEZ series) |
Below are the areas covered for each company under the top global manufacturers:
Recent Developments
- In June 2024, Philips launched DreamStation, which is the first post-recall BiPP regained 14% of Europe’s home-care market share by addressing safety concerns with new particulate-free motors.
- In March 2024, ResMed announced the launch of AirCurve 11, which reduced manual titration needs by 40%, driving adoption in sleep clinics per FDA 510(k) clearance data.
Author Credits: Radhika Pawar
- Report ID: 7736
- Published Date: Jun 10, 2025
- Report Format: PDF, PPT
